

# Global CD30 (TNFRSF8) Antibody Market Growth 2022-2028

<https://marketpublishers.com/r/GBE1C5FBE4FCEN.html>

Date: November 2022

Pages: 114

Price: US\$ 3,660.00 (Single User License)

ID: GBE1C5FBE4FCEN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

CD30 (TNFRSF8) Antibody is an unconjugated antibody to CD30.

The global market for CD30 (TNFRSF8) Antibody is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC CD30 (TNFRSF8) Antibody market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States CD30 (TNFRSF8) Antibody market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe CD30 (TNFRSF8) Antibody market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China CD30 (TNFRSF8) Antibody market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key CD30 (TNFRSF8) Antibody players cover Sino Biological, Inc., Bio-Techne, Thermo Fisher Scientific (China) Co., Ltd., Boster Biological Technology and MyBiosource, Inc., etc. In terms of revenue, the global largest two companies occupy a

share nearly % in 2021.

## Report Coverage

This latest report provides a deep insight into the global CD30 (TNFRSF8) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global CD30 (TNFRSF8) Antibody market, with both quantitative and qualitative data, to help readers understand how the CD30 (TNFRSF8) Antibody market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

## Market Segmentation:

The study segments the CD30 (TNFRSF8) Antibody market and forecasts the market size by Type (Monoclonal Antibody and Polyclonal Antibody,), by Application (Flow Cytometry, ELISA, Western Blot and Immunofluorescence), and region (APAC, Americas, Europe, and Middle East & Africa).

### Segmentation by type

Monoclonal Antibody

Polyclonal Antibody

### Segmentation by application

Flow Cytometry

ELISA

Western Blot

Immunofluorescence

Other

## Segmentation by region

### Americas

United States

Canada

Mexico

Brazil

### APAC

China

Japan

Korea

Southeast Asia

India

Australia

### Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

Sino Biological, Inc.

Bio-Techne

Thermo Fisher Scientific (China) Co., Ltd.

Boster Biological Technology

MyBiosource, Inc.

Abeomics Inc.

Abbexa

Cell Signaling Technology, Inc.

Creative Diagnostics

OriGene Technologies, Inc.

Merck

Cayman Chemical

CUSABIO

Biotium

BioLegend

Abcepta

ProSci Incorporated

## Chapter Introduction

Chapter 1: Scope of CD30 (TNFRSF8) Antibody, Research Methodology, etc.

Chapter 2: Executive Summary, global CD30 (TNFRSF8) Antibody market size (sales and revenue) and CAGR, CD30 (TNFRSF8) Antibody market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: CD30 (TNFRSF8) Antibody sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global CD30 (TNFRSF8) Antibody sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global CD30 (TNFRSF8) Antibody market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including Sino Biological, Inc., Bio-Techne, Thermo Fisher Scientific (China) Co., Ltd., Boster Biological Technology, MyBiosource, Inc., Abeomics Inc., Abbexa, Cell Signaling Technology, Inc. and Creative Diagnostics, etc.

Chapter 14: Research Findings and Conclusion

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global CD30 (TNFRSF8) Antibody Annual Sales 2017-2028
  - 2.1.2 World Current & Future Analysis for CD30 (TNFRSF8) Antibody by Geographic Region, 2017, 2022 & 2028
  - 2.1.3 World Current & Future Analysis for CD30 (TNFRSF8) Antibody by Country/Region, 2017, 2022 & 2028
- 2.2 CD30 (TNFRSF8) Antibody Segment by Type
  - 2.2.1 Monoclonal Antibody
  - 2.2.2 Polyclonal Antibody
- 2.3 CD30 (TNFRSF8) Antibody Sales by Type
  - 2.3.1 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
  - 2.3.2 Global CD30 (TNFRSF8) Antibody Revenue and Market Share by Type (2017-2022)
  - 2.3.3 Global CD30 (TNFRSF8) Antibody Sale Price by Type (2017-2022)
- 2.4 CD30 (TNFRSF8) Antibody Segment by Application
  - 2.4.1 Flow Cytometry
  - 2.4.2 ELISA
  - 2.4.3 Western Blot
  - 2.4.4 Immunofluorescence
  - 2.4.5 Other
- 2.5 CD30 (TNFRSF8) Antibody Sales by Application
  - 2.5.1 Global CD30 (TNFRSF8) Antibody Sale Market Share by Application (2017-2022)
  - 2.5.2 Global CD30 (TNFRSF8) Antibody Revenue and Market Share by Application (2017-2022)

2.5.3 Global CD30 (TNFRSF8) Antibody Sale Price by Application (2017-2022)

### **3 GLOBAL CD30 (TNFRSF8) ANTIBODY BY COMPANY**

3.1 Global CD30 (TNFRSF8) Antibody Breakdown Data by Company

3.1.1 Global CD30 (TNFRSF8) Antibody Annual Sales by Company (2020-2022)

3.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Company (2020-2022)

3.2 Global CD30 (TNFRSF8) Antibody Annual Revenue by Company (2020-2022)

3.2.1 Global CD30 (TNFRSF8) Antibody Revenue by Company (2020-2022)

3.2.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Company (2020-2022)

3.3 Global CD30 (TNFRSF8) Antibody Sale Price by Company

3.4 Key Manufacturers CD30 (TNFRSF8) Antibody Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers CD30 (TNFRSF8) Antibody Product Location Distribution

3.4.2 Players CD30 (TNFRSF8) Antibody Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR CD30 (TNFRSF8) ANTIBODY BY GEOGRAPHIC REGION**

4.1 World Historic CD30 (TNFRSF8) Antibody Market Size by Geographic Region (2017-2022)

4.1.1 Global CD30 (TNFRSF8) Antibody Annual Sales by Geographic Region (2017-2022)

4.1.2 Global CD30 (TNFRSF8) Antibody Annual Revenue by Geographic Region

4.2 World Historic CD30 (TNFRSF8) Antibody Market Size by Country/Region (2017-2022)

4.2.1 Global CD30 (TNFRSF8) Antibody Annual Sales by Country/Region (2017-2022)

4.2.2 Global CD30 (TNFRSF8) Antibody Annual Revenue by Country/Region

4.3 Americas CD30 (TNFRSF8) Antibody Sales Growth

4.4 APAC CD30 (TNFRSF8) Antibody Sales Growth

4.5 Europe CD30 (TNFRSF8) Antibody Sales Growth

4.6 Middle East & Africa CD30 (TNFRSF8) Antibody Sales Growth



## **5 AMERICAS**

### 5.1 Americas CD30 (TNFRSF8) Antibody Sales by Country

5.1.1 Americas CD30 (TNFRSF8) Antibody Sales by Country (2017-2022)

5.1.2 Americas CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022)

### 5.2 Americas CD30 (TNFRSF8) Antibody Sales by Type

### 5.3 Americas CD30 (TNFRSF8) Antibody Sales by Application

### 5.4 United States

### 5.5 Canada

### 5.6 Mexico

### 5.7 Brazil

## **6 APAC**

### 6.1 APAC CD30 (TNFRSF8) Antibody Sales by Region

6.1.1 APAC CD30 (TNFRSF8) Antibody Sales by Region (2017-2022)

6.1.2 APAC CD30 (TNFRSF8) Antibody Revenue by Region (2017-2022)

### 6.2 APAC CD30 (TNFRSF8) Antibody Sales by Type

### 6.3 APAC CD30 (TNFRSF8) Antibody Sales by Application

### 6.4 China

### 6.5 Japan

### 6.6 South Korea

### 6.7 Southeast Asia

### 6.8 India

### 6.9 Australia

### 6.10 China Taiwan

## **7 EUROPE**

### 7.1 Europe CD30 (TNFRSF8) Antibody by Country

7.1.1 Europe CD30 (TNFRSF8) Antibody Sales by Country (2017-2022)

7.1.2 Europe CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022)

### 7.2 Europe CD30 (TNFRSF8) Antibody Sales by Type

### 7.3 Europe CD30 (TNFRSF8) Antibody Sales by Application

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa CD30 (TNFRSF8) Antibody by Country

8.1.1 Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Country (2017-2022)

8.1.2 Middle East & Africa CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022)

8.2 Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Type

8.3 Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of CD30 (TNFRSF8) Antibody

10.3 Manufacturing Process Analysis of CD30 (TNFRSF8) Antibody

10.4 Industry Chain Structure of CD30 (TNFRSF8) Antibody

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 CD30 (TNFRSF8) Antibody Distributors

11.3 CD30 (TNFRSF8) Antibody Customer

## **12 WORLD FORECAST REVIEW FOR CD30 (TNFRSF8) ANTIBODY BY GEOGRAPHIC REGION**

- 12.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region
  - 12.1.1 Global CD30 (TNFRSF8) Antibody Forecast by Region (2023-2028)
  - 12.1.2 Global CD30 (TNFRSF8) Antibody Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global CD30 (TNFRSF8) Antibody Forecast by Type
- 12.7 Global CD30 (TNFRSF8) Antibody Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

- 13.1 Sino Biological, Inc.
  - 13.1.1 Sino Biological, Inc. Company Information
  - 13.1.2 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Offered
  - 13.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.1.4 Sino Biological, Inc. Main Business Overview
  - 13.1.5 Sino Biological, Inc. Latest Developments
- 13.2 Bio-Techne
  - 13.2.1 Bio-Techne Company Information
  - 13.2.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Offered
  - 13.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.2.4 Bio-Techne Main Business Overview
  - 13.2.5 Bio-Techne Latest Developments
- 13.3 Thermo Fisher Scientific (China) Co., Ltd.
  - 13.3.1 Thermo Fisher Scientific (China) Co., Ltd. Company Information
  - 13.3.2 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Offered
  - 13.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.3.4 Thermo Fisher Scientific (China) Co., Ltd. Main Business Overview
  - 13.3.5 Thermo Fisher Scientific (China) Co., Ltd. Latest Developments
- 13.4 Boster Biological Technology
  - 13.4.1 Boster Biological Technology Company Information
  - 13.4.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Offered

- 13.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 Boster Biological Technology Main Business Overview
- 13.4.5 Boster Biological Technology Latest Developments
- 13.5 MyBiosource, Inc.
  - 13.5.1 MyBiosource, Inc. Company Information
  - 13.5.2 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Offered
  - 13.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.5.4 MyBiosource, Inc. Main Business Overview
  - 13.5.5 MyBiosource, Inc. Latest Developments
- 13.6 Abeomics Inc.
  - 13.6.1 Abeomics Inc. Company Information
  - 13.6.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Offered
  - 13.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.6.4 Abeomics Inc. Main Business Overview
  - 13.6.5 Abeomics Inc. Latest Developments
- 13.7 Abbexa
  - 13.7.1 Abbexa Company Information
  - 13.7.2 Abbexa CD30 (TNFRSF8) Antibody Product Offered
  - 13.7.3 Abbexa CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.7.4 Abbexa Main Business Overview
  - 13.7.5 Abbexa Latest Developments
- 13.8 Cell Signaling Technology, Inc.
  - 13.8.1 Cell Signaling Technology, Inc. Company Information
  - 13.8.2 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Offered
  - 13.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.8.4 Cell Signaling Technology, Inc. Main Business Overview
  - 13.8.5 Cell Signaling Technology, Inc. Latest Developments
- 13.9 Creative Diagnostics
  - 13.9.1 Creative Diagnostics Company Information
  - 13.9.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Offered
  - 13.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.9.4 Creative Diagnostics Main Business Overview
  - 13.9.5 Creative Diagnostics Latest Developments

### 13.10 OriGene Technologies, Inc.

13.10.1 OriGene Technologies, Inc. Company Information

13.10.2 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Offered

13.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 OriGene Technologies, Inc. Main Business Overview

13.10.5 OriGene Technologies, Inc. Latest Developments

### 13.11 Merck

13.11.1 Merck Company Information

13.11.2 Merck CD30 (TNFRSF8) Antibody Product Offered

13.11.3 Merck CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Merck Main Business Overview

13.11.5 Merck Latest Developments

### 13.12 Cayman Chemical

13.12.1 Cayman Chemical Company Information

13.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Offered

13.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Cayman Chemical Main Business Overview

13.12.5 Cayman Chemical Latest Developments

### 13.13 CUSABIO

13.13.1 CUSABIO Company Information

13.13.2 CUSABIO CD30 (TNFRSF8) Antibody Product Offered

13.13.3 CUSABIO CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 CUSABIO Main Business Overview

13.13.5 CUSABIO Latest Developments

### 13.14 Biotium

13.14.1 Biotium Company Information

13.14.2 Biotium CD30 (TNFRSF8) Antibody Product Offered

13.14.3 Biotium CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Biotium Main Business Overview

13.14.5 Biotium Latest Developments

### 13.15 BioLegend

13.15.1 BioLegend Company Information

13.15.2 BioLegend CD30 (TNFRSF8) Antibody Product Offered

13.15.3 BioLegend CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross

## Margin (2020-2022)

13.15.4 BioLegend Main Business Overview

13.15.5 BioLegend Latest Developments

## 13.16 Abcepta

13.16.1 Abcepta Company Information

13.16.2 Abcepta CD30 (TNFRSF8) Antibody Product Offered

13.16.3 Abcepta CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 Abcepta Main Business Overview

13.16.5 Abcepta Latest Developments

## 13.17 ProSci Incorporated

13.17.1 ProSci Incorporated Company Information

13.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Offered

13.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 ProSci Incorporated Main Business Overview

13.17.5 ProSci Incorporated Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. CD30 (TNFRSF8) Antibody Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. CD30 (TNFRSF8) Antibody Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Monoclonal Antibody

Table 4. Major Players of Polyclonal Antibody

Table 5. Global CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)

Table 6. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)

Table 7. Global CD30 (TNFRSF8) Antibody Revenue by Type (2017-2022) & (\$ million)

Table 8. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2017-2022)

Table 9. Global CD30 (TNFRSF8) Antibody Sale Price by Type (2017-2022) & (US\$/Unit)

Table 10. Global CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)

Table 11. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)

Table 12. Global CD30 (TNFRSF8) Antibody Revenue by Application (2017-2022)

Table 13. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2017-2022)

Table 14. Global CD30 (TNFRSF8) Antibody Sale Price by Application (2017-2022) & (US\$/Unit)

Table 15. Global CD30 (TNFRSF8) Antibody Sales by Company (2020-2022) & (K Units)

Table 16. Global CD30 (TNFRSF8) Antibody Sales Market Share by Company (2020-2022)

Table 17. Global CD30 (TNFRSF8) Antibody Revenue by Company (2020-2022) (\$ Millions)

Table 18. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Company (2020-2022)

Table 19. Global CD30 (TNFRSF8) Antibody Sale Price by Company (2020-2022) & (US\$/Unit)

Table 20. Key Manufacturers CD30 (TNFRSF8) Antibody Producing Area Distribution and Sales Area

Table 21. Players CD30 (TNFRSF8) Antibody Products Offered

Table 22. CD30 (TNFRSF8) Antibody Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global CD30 (TNFRSF8) Antibody Sales by Geographic Region (2017-2022) & (K Units)

Table 26. Global CD30 (TNFRSF8) Antibody Sales Market Share Geographic Region (2017-2022)

Table 27. Global CD30 (TNFRSF8) Antibody Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 28. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Geographic Region (2017-2022)

Table 29. Global CD30 (TNFRSF8) Antibody Sales by Country/Region (2017-2022) & (K Units)

Table 30. Global CD30 (TNFRSF8) Antibody Sales Market Share by Country/Region (2017-2022)

Table 31. Global CD30 (TNFRSF8) Antibody Revenue by Country/Region (2017-2022) & (\$ millions)

Table 32. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Country/Region (2017-2022)

Table 33. Americas CD30 (TNFRSF8) Antibody Sales by Country (2017-2022) & (K Units)

Table 34. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Country (2017-2022)

Table 35. Americas CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022) & (\$ Millions)

Table 36. Americas CD30 (TNFRSF8) Antibody Revenue Market Share by Country (2017-2022)

Table 37. Americas CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)

Table 38. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)

Table 39. Americas CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)

Table 40. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)

Table 41. APAC CD30 (TNFRSF8) Antibody Sales by Region (2017-2022) & (K Units)

Table 42. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Region (2017-2022)

Table 43. APAC CD30 (TNFRSF8) Antibody Revenue by Region (2017-2022) & (\$



Millions)

Table 44. APAC CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2017-2022)

Table 45. APAC CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)

Table 46. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)

Table 47. APAC CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)

Table 48. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)

Table 49. Europe CD30 (TNFRSF8) Antibody Sales by Country (2017-2022) & (K Units)

Table 50. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country (2017-2022)

Table 51. Europe CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022) & (\$ Millions)

Table 52. Europe CD30 (TNFRSF8) Antibody Revenue Market Share by Country (2017-2022)

Table 53. Europe CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)

Table 54. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)

Table 55. Europe CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)

Table 56. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)

Table 57. Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Country (2017-2022) & (K Units)

Table 58. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Country (2017-2022)

Table 59. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022) & (\$ Millions)

Table 60. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue Market Share by Country (2017-2022)

Table 61. Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)

Table 62. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)

Table 63. Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)

Table 64. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)

Table 65. Key Market Drivers & Growth Opportunities of CD30 (TNFRSF8) Antibody

- Table 66. Key Market Challenges & Risks of CD30 (TNFRSF8) Antibody
- Table 67. Key Industry Trends of CD30 (TNFRSF8) Antibody
- Table 68. CD30 (TNFRSF8) Antibody Raw Material
- Table 69. Key Suppliers of Raw Materials
- Table 70. CD30 (TNFRSF8) Antibody Distributors List
- Table 71. CD30 (TNFRSF8) Antibody Customer List
- Table 72. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2023-2028) & (K Units)
- Table 73. Global CD30 (TNFRSF8) Antibody Sales Market Forecast by Region
- Table 74. Global CD30 (TNFRSF8) Antibody Revenue Forecast by Region (2023-2028) & (\$ millions)
- Table 75. Global CD30 (TNFRSF8) Antibody Revenue Market Share Forecast by Region (2023-2028)
- Table 76. Americas CD30 (TNFRSF8) Antibody Sales Forecast by Country (2023-2028) & (K Units)
- Table 77. Americas CD30 (TNFRSF8) Antibody Revenue Forecast by Country (2023-2028) & (\$ millions)
- Table 78. APAC CD30 (TNFRSF8) Antibody Sales Forecast by Region (2023-2028) & (K Units)
- Table 79. APAC CD30 (TNFRSF8) Antibody Revenue Forecast by Region (2023-2028) & (\$ millions)
- Table 80. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2023-2028) & (K Units)
- Table 81. Europe CD30 (TNFRSF8) Antibody Revenue Forecast by Country (2023-2028) & (\$ millions)
- Table 82. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Forecast by Country (2023-2028) & (K Units)
- Table 83. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue Forecast by Country (2023-2028) & (\$ millions)
- Table 84. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2023-2028) & (K Units)
- Table 85. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2023-2028)
- Table 86. Global CD30 (TNFRSF8) Antibody Revenue Forecast by Type (2023-2028) & (\$ Millions)
- Table 87. Global CD30 (TNFRSF8) Antibody Revenue Market Share Forecast by Type (2023-2028)
- Table 88. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2023-2028) & (K Units)

Table 89. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Application (2023-2028)

Table 90. Global CD30 (TNFRSF8) Antibody Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 91. Global CD30 (TNFRSF8) Antibody Revenue Market Share Forecast by Application (2023-2028)

Table 92. Sino Biological, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 93. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Offered

Table 94. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 95. Sino Biological, Inc. Main Business

Table 96. Sino Biological, Inc. Latest Developments

Table 97. Bio-Techne Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 98. Bio-Techne CD30 (TNFRSF8) Antibody Product Offered

Table 99. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 100. Bio-Techne Main Business

Table 101. Bio-Techne Latest Developments

Table 102. Thermo Fisher Scientific (China) Co., Ltd. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 103. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Offered

Table 104. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 105. Thermo Fisher Scientific (China) Co., Ltd. Main Business

Table 106. Thermo Fisher Scientific (China) Co., Ltd. Latest Developments

Table 107. Boster Biological Technology Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 108. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Offered

Table 109. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 110. Boster Biological Technology Main Business

Table 111. Boster Biological Technology Latest Developments

Table 112. MyBiosource, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 113. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Offered

Table 114. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 115. MyBiosource, Inc. Main Business

Table 116. MyBiosource, Inc. Latest Developments

Table 117. Abeomics Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 118. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Offered

Table 119. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 120. Abeomics Inc. Main Business

Table 121. Abeomics Inc. Latest Developments

Table 122. Abbexa Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 123. Abbexa CD30 (TNFRSF8) Antibody Product Offered

Table 124. Abbexa CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 125. Abbexa Main Business

Table 126. Abbexa Latest Developments

Table 127. Cell Signaling Technology, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 128. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Offered

Table 129. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 130. Cell Signaling Technology, Inc. Main Business

Table 131. Cell Signaling Technology, Inc. Latest Developments

Table 132. Creative Diagnostics Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 133. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Offered

Table 134. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 135. Creative Diagnostics Main Business

Table 136. Creative Diagnostics Latest Developments

Table 137. OriGene Technologies, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 138. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Offered

Table 139. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 140. OriGene Technologies, Inc. Main Business

Table 141. OriGene Technologies, Inc. Latest Developments

Table 142. Merck Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base,

## Sales Area and Its Competitors

Table 143. Merck CD30 (TNFRSF8) Antibody Product Offered

Table 144. Merck CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 145. Merck Main Business

Table 146. Merck Latest Developments

Table 147. Cayman Chemical Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 148. Cayman Chemical CD30 (TNFRSF8) Antibody Product Offered

Table 149. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 150. Cayman Chemical Main Business

Table 151. Cayman Chemical Latest Developments

Table 152. CUSABIO Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 153. CUSABIO CD30 (TNFRSF8) Antibody Product Offered

Table 154. CUSABIO CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 155. CUSABIO Main Business

Table 156. CUSABIO Latest Developments

Table 157. Biotium Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 158. Biotium CD30 (TNFRSF8) Antibody Product Offered

Table 159. Biotium CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 160. Biotium Main Business

Table 161. Biotium Latest Developments

Table 162. BioLegend Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 163. BioLegend CD30 (TNFRSF8) Antibody Product Offered

Table 164. BioLegend CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 165. BioLegend Main Business

Table 166. BioLegend Latest Developments

Table 167. Abcepta Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 168. Abcepta CD30 (TNFRSF8) Antibody Product Offered

Table 169. Abcepta CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 170. Abcepta Main Business

Table 171. Abcepta Latest Developments

Table 172. ProSci Incorporated Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors

Table 173. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Offered

Table 174. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 175. ProSci Incorporated Main Business

Table 176. ProSci Incorporated Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of CD30 (TNFRSF8) Antibody
- Figure 2. CD30 (TNFRSF8) Antibody Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global CD30 (TNFRSF8) Antibody Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global CD30 (TNFRSF8) Antibody Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. CD30 (TNFRSF8) Antibody Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Monoclonal Antibody
- Figure 10. Product Picture of Polyclonal Antibody
- Figure 11. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type in 2021
- Figure 12. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2017-2022)
- Figure 13. CD30 (TNFRSF8) Antibody Consumed in Flow Cytometry
- Figure 14. Global CD30 (TNFRSF8) Antibody Market: Flow Cytometry (2017-2022) & (K Units)
- Figure 15. CD30 (TNFRSF8) Antibody Consumed in ELISA
- Figure 16. Global CD30 (TNFRSF8) Antibody Market: ELISA (2017-2022) & (K Units)
- Figure 17. CD30 (TNFRSF8) Antibody Consumed in Western Blot
- Figure 18. Global CD30 (TNFRSF8) Antibody Market: Western Blot (2017-2022) & (K Units)
- Figure 19. CD30 (TNFRSF8) Antibody Consumed in Immunofluorescence
- Figure 20. Global CD30 (TNFRSF8) Antibody Market: Immunofluorescence (2017-2022) & (K Units)
- Figure 21. CD30 (TNFRSF8) Antibody Consumed in Other
- Figure 22. Global CD30 (TNFRSF8) Antibody Market: Other (2017-2022) & (K Units)
- Figure 23. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
- Figure 24. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application in 2021
- Figure 25. CD30 (TNFRSF8) Antibody Revenue Market by Company in 2021 (\$ Million)
- Figure 26. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Company in 2021
- Figure 27. Global CD30 (TNFRSF8) Antibody Sales Market Share by Geographic

Region (2017-2022)

Figure 28. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Geographic Region in 2021

Figure 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2017-2022)

Figure 30. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Country/Region in 2021

Figure 31. Americas CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)

Figure 32. Americas CD30 (TNFRSF8) Antibody Revenue 2017-2022 (\$ Millions)

Figure 33. APAC CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)

Figure 34. APAC CD30 (TNFRSF8) Antibody Revenue 2017-2022 (\$ Millions)

Figure 35. Europe CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)

Figure 36. Europe CD30 (TNFRSF8) Antibody Revenue 2017-2022 (\$ Millions)

Figure 37. Middle East & Africa CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)

Figure 38. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue 2017-2022 (\$ Millions)

Figure 39. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2021

Figure 40. Americas CD30 (TNFRSF8) Antibody Revenue Market Share by Country in 2021

Figure 41. United States CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 42. Canada CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 43. Mexico CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 44. Brazil CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 45. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2021

Figure 46. APAC CD30 (TNFRSF8) Antibody Revenue Market Share by Regions in 2021

Figure 47. China CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 48. Japan CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 49. South Korea CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 50. Southeast Asia CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 51. India CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 52. Australia CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 53. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2021

Figure 54. Europe CD30 (TNFRSF8) Antibody Revenue Market Share by Country in



2021

Figure 55. Germany CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 56. France CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 57. UK CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Italy CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Russia CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 60. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2021

Figure 61. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue Market Share by Country in 2021

Figure 62. Egypt CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 63. South Africa CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 64. Israel CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 65. Turkey CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 66. GCC Country CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 (\$ Millions)

Figure 67. Manufacturing Cost Structure Analysis of CD30 (TNFRSF8) Antibody in 2021

Figure 68. Manufacturing Process Analysis of CD30 (TNFRSF8) Antibody

Figure 69. Industry Chain Structure of CD30 (TNFRSF8) Antibody

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles

## I would like to order

Product name: Global CD30 (TNFRSF8) Antibody Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/GBE1C5FBE4FCEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBE1C5FBE4FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970